Dr Agarwal's Hea

Which are the latest news on Dr Agarwal's Hea?

Why is Dr Agarwals Health Care Ltd falling/rising?

As of 05-Sep, Dr Agarwals Health Care Ltd's stock price has risen to 514.15, driven by strong financial health, positive market sentiment, and outperformance against benchmarks. Key factors include a low Debt to EBITDA ratio, significant annual sales growth, and consistent positive quarterly results.

As of 05-Sep, Dr Agarwals Health Care Ltd is experiencing a rise in its stock price, currently at 514.15, reflecting an increase of 1.6 (0.31%). This upward movement can be attributed to several factors. <BR><BR>Firstly, the stock has outperformed its sector by 1.81% today, indicating strong relative performance. Additionally, Dr Agarwals is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which is a positive signal for investors. <BR><BR>Moreover, the company has demonstrated robust financial health, with a low Debt to EBITDA ratio of 1.87 times, showcasing its strong ability to service debt. The annual growth rate of net sales at 26.90% further supports the company's healthy long-term growth prospects. <BR><BR>The company has also reported positive results for the last six consecutive quarters, with net sales reaching a high of Rs 614.02 crore and PBT (Profit Before Tax) at Rs 68.73 crore, which reflects strong operational performance. <BR><BR>Furthermore, the stock has generated a return of 23.11% over the past year, significantly outperforming the market, which has seen a return of only 1.51%. The high institutional holdings at 65.68% suggest that knowledgeable investors have confidence in the company's fundamentals, which can positively influence stock price movements.<BR><BR>In summary, the combination of strong financial performance, positive market sentiment, and outperformance against benchmarks contributes to the rising stock price of Dr Agarwals Health Care Ltd.

Should I buy, sell or hold Dr Agarwals Health Care Ltd?

What does Dr Agarwal's Hea do?

Dr Agarwal's Health Care Ltd is a small-cap hospital company established in 2010, with net sales of 614 Cr and a net profit of 45 Cr as of June 2026. Key metrics include a P/E ratio of 111.00 and a market cap of INR 15,934 Cr.

Overview:<BR>Dr Agarwal's Health Care Ltd operates in the hospital industry and is categorized as a small-cap company.<BR><BR>History:<BR>The company was incorporated in 2010 and commenced operations shortly thereafter. The latest quarterly results reported are for June 2026, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>Net Sales: 614 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 45 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 15,934 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 111.00 <BR>Industry P/E: 67 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.39 <BR>Return on Equity: 6.53% <BR>Price to Book: 7.90 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Dr Agarwal's Hea?

Dr Agarwal's Hea's peers include Fortis Health, Aster DM Quality, Global Health, Narayana Hrudaya, Krishna Institute, Rainbow Children, Jupiter Life Line, and Yatharth Hospital. Key insights show Aster DM Quality has the highest 1-year return at 25.77%, while Dr Agarwal's Hea has an 18.31% return, and Rainbow Children has the lowest at -5.86%.

Peers: The peers of Dr Agarwal's Hea are Fortis Health., Aster DM Quality, Global Health, Narayana Hrudaya, Krishna Institu., Rainbow Child., Health.Global, Jupiter Life Lin, and Yatharth Hospit.<BR><BR>Quality Snapshot: Excellent management risk is observed at Global Health, Narayana Hrudaya, Aster DM Quality, and Jupiter Life Lin, while Average management risk is found at Fortis Health. and Health.Global. Good growth is seen at Dr Agarwal's Hea, Fortis Health., Global Health, and Narayana Hrudaya, while Below Average growth is noted at Aster DM Quality, Krishna Institu., Rainbow Child., and Jupiter Life Lin. Good capital structure is present at Fortis Health., Narayana Hrudaya, Dr Agarwal's Hea, Krishna Institu., and Rainbow Child., while Average capital structure is found at Aster DM Quality and Health.Global, and Excellent capital structure is noted at Global Health and Jupiter Life Lin.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Aster DM Quality at 25.77%, while the lowest is Rainbow Child. at -5.86%. Dr Agarwal's Hea has a 1-year return of 18.31%, which is significantly higher than Rainbow Child. but lower than Aster DM Quality. Additionally, the peers with negative six-month returns include Fortis Health. and Krishna Institu.

How big is Dr Agarwal's Hea?

As of 31st August, Dr Agarwals Health Care Ltd has a market capitalization of 15,934.00 Cr, with recent Net Sales of 2206.68 Cr and a Net Profit of 148.37 Cr.

As of 31st August, Dr Agarwals Health Care Ltd has a market capitalization of 15,934.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 2206.68 Cr and a Net Profit of 148.37 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 1,866.59 Cr and Total Assets of 3,639.60 Cr.

Are Dr Agarwals Health Care Ltd latest results good or bad?

Dr Agarwal's Health Care Ltd's latest Q1 FY27 results are generally positive, with a 50.52% increase in net profit and a 25.97% rise in net sales. However, concerns about declining operating margins due to rising costs suggest challenges ahead.

Dr Agarwal's Health Care Ltd's latest results for Q1 FY27 can be considered good overall, showcasing strong growth in both net profit and net sales. The consolidated net profit reached ₹45.23 crores, reflecting a significant year-on-year increase of 50.52% and a sequential rise of 13.90%. Similarly, net sales amounted to ₹614.02 crores, which is a robust 25.97% growth compared to the same quarter last year and an 8.85% increase from the previous quarter.<BR><BR>However, there are some concerns regarding operating margins. The operating margin decreased slightly to 27.75%, down 87 basis points from the previous quarter, primarily due to rising employee costs. While the profit after tax margin improved marginally to 8.96%, it remains below the company's historical peak.<BR><BR>In summary, while the company has demonstrated impressive revenue growth and profitability improvements, the pressure on margins and rising costs are factors that warrant close monitoring. Overall, the results indicate a solid performance, but the company faces challenges that could impact future profitability.

When is the next results date for Dr Agarwals Health Care Ltd?

The next results date for Dr Agarwals Health Care Ltd is August 4, 2026.

The next results date for Dr Agarwals Health Care Ltd is scheduled for August 4, 2026.

How has been the historical performance of Dr Agarwal's Hea?

Dr Agarwal's Hea has shown significant growth over the past three years, with net sales increasing from 1,017.98 Cr in Mar'23 to 1,711.00 Cr in Mar'25, and operating profit rising from 283.86 Cr to 502.40 Cr during the same period, alongside a substantial increase in total assets. Overall, the company demonstrates a solid performance trajectory with rising revenues and profits.

Answer:<BR>The historical performance of Dr Agarwal's Hea shows significant growth in various financial metrics over the past three years.<BR><BR>Breakdown:<BR>Dr Agarwal's Hea has demonstrated a strong upward trend in net sales, increasing from 1,017.98 Cr in Mar'23 to 1,711.00 Cr in Mar'25. Total operating income followed suit, rising from 1,017.98 Cr to 1,711.00 Cr during the same period. The company's total expenditure also grew, reaching 1,254.62 Cr in Mar'25, up from 747.63 Cr in Mar'23. Operating profit (PBDIT) saw a notable increase, climbing from 283.86 Cr in Mar'23 to 502.40 Cr in Mar'25. Profit before tax also improved, moving from 83.59 Cr in Mar'23 to 159.85 Cr in Mar'25, while profit after tax showed a slight fluctuation, peaking at 110.34 Cr in Mar'25 compared to 103.23 Cr in Mar'23. The consolidated net profit remained relatively stable, with a slight increase from 83.06 Cr in Mar'24 to 83.46 Cr in Mar'25. The company's total assets rose significantly from 1,769.72 Cr in Mar'23 to 3,639.60 Cr in Mar'25, reflecting robust growth in shareholder's funds and reserves. Cash flow from operating activities also improved, reaching 360.00 Cr in Mar'25, while cash flow from investing activities remained negative at -750.00 Cr, indicating ongoing investments. Overall, Dr Agarwal's Hea has shown a solid performance trajectory with increasing revenues and profits, alongside a growing asset base.

Is Dr Agarwal's Hea overvalued or undervalued?

As of September 12, 2025, Dr Agarwal's Healthcare is considered very expensive and overvalued with a PE ratio of 160.64, significantly higher than its peers, and a low ROE of 4.58%, making it not a compelling investment at its current price of 433.10.

As of 12 September 2025, the valuation grade for Dr Agarwal's Healthcare has moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently deemed overvalued, with a PE ratio of 160.64, a Price to Book Value of 7.36, and an EV to EBITDA of 31.07. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Dr Agarwal's Healthcare stands out with a notably higher PE ratio than Max Healthcare, which has a PE of 95.48, and Apollo Hospitals, which is at 71.91. Additionally, the company's ROE is only 4.58%, which is considerably lower than the industry average, further reinforcing the overvaluation narrative. Despite a recent stock return of 1.55% over the past week, which slightly outperformed the Sensex's 1.48%, the overall valuation metrics suggest that Dr Agarwal's Healthcare is not a compelling investment at its current price of 433.10.

Who are the top shareholders of the Dr Agarwal's Hea?

The top shareholders of Dr Agarwal's Hea are primarily Foreign Institutional Investors (FIIs) with 60.62%, led by Hyperion Investments Pte Ltd at 23.17%. Dr. Athiya Agarwal is the largest individual shareholder at 5.99%, while mutual funds hold 3.84% and individual investors own 1.61%.

The top shareholders of Dr Agarwal's Hea include a mix of institutional and individual investors. The majority of the shares are held by Foreign Institutional Investors (FIIs), who own approximately 60.62% of the company. The highest public shareholder is Hyperion Investments Pte Ltd, holding 23.17%. Among individual stakeholders, Dr. Athiya Agarwal is the promoter with the highest holding at 5.99%. Additionally, mutual funds are represented by six schemes, collectively holding 3.84%. Individual investors account for 1.61% of the shares.

Has Dr Agarwal's Hea declared dividend?

No Dividend History Available